Commonwealth Equity Services Inc boosted its position in Pfizer Inc. (NYSE:PFE) by 2.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,236,320 shares of the biopharmaceutical company’s stock after buying an additional 43,838 shares during the period. Pfizer makes up 0.7% of Commonwealth Equity Services Inc’s portfolio, making the stock its 28th largest position. Commonwealth Equity Services Inc’s holdings in Pfizer were worth $78,741,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of PFE. BlackRock Fund Advisors boosted its stake in shares of Pfizer by 1.5% in the first quarter. BlackRock Fund Advisors now owns 92,489,121 shares of the biopharmaceutical company’s stock worth $2,741,378,000 after buying an additional 1,403,646 shares during the period. Wellington Management Group LLP boosted its stake in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock worth $2,454,601,000 after buying an additional 3,936,078 shares during the period. Franklin Resources Inc. boosted its stake in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares during the period. BlackRock Group LTD boosted its stake in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Pfizer by 1.7% in the first quarter. Legal & General Group Plc now owns 29,385,795 shares of the biopharmaceutical company’s stock worth $871,079,000 after buying an additional 488,194 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.259% during mid-day trading on Friday, hitting $32.845. 3,340,721 shares of the stock were exchanged. Pfizer Inc. has a 12 month low of $28.25 and a 12 month high of $37.39. The stock has a market cap of $199.23 billion, a PE ratio of 29.118 and a beta of 0.86. The stock’s 50 day moving average is $34.08 and its 200-day moving average is $34.25.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.56 earnings per share. On average, analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is currently 95.24%.
A number of equities research analysts have recently issued reports on the stock. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price objective for the company in a research note on Tuesday, August 2nd. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a research report on Monday, September 26th. Piper Jaffray Cos. reissued an “overweight” rating and set a $54.00 price target on shares of Pfizer in a research report on Monday, June 27th. BMO Capital Markets reissued a “buy” rating and set a $40.00 price target on shares of Pfizer in a research report on Thursday, July 21st. Finally, JPMorgan Chase & Co. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 25th. Eleven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.59.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.